Shawn Flanagan, PhD

VP, Clinical Pharmacology and Early Development
Cidara Therapeutics

Disclosure: Cidara Therapeutics, Inc. (Employee, Shareholder)

Shawn Flanagan, PhD, is Vice President of Clinical Pharmacology and Early Development at Cidara Therapeutics, Inc. He is a highly accomplished and influential scientific leader with diverse knowledge of drug development and translational research. Shawn has over 25 years in the Pharmaceutical Industry and over a decade working in the therapeutic area of Infectious Diseases.

Poster(s):

637 - Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
1174 - Phase 2 STRIVE Clinical Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrates Consistent Trough Concentrations Across Diverse Patient Populations
1286 - Pharmacokinetics, Excretion, and Mass Balance of [¹⁴C]-Rezafungin Following Intravenous (IV) Administration in Healthy Adults